Compare Stocks: BGM, CGTX, CPIX, and PYPD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$0.25 -3.1%	$0.28	$0.23 ▼ $11.79	$24.40M	1.8	109,131 shs	38,832 shs
CGTX Cognition Therapeutics	$1.04 -1.9%	$1.00	$0.55 ▼ $2.05	$98.90M	1.79	348,518 shs	336,211 shs
CPIX Cumberland Pharmaceuticals	$7.32 +1.8%	$7.29	$1.85 ▼ $9.28	$109.68M	0.13	54,920 shs	27,559 shs
PYPD PolyPid	$5.21 +3.6%	$4.87	$3.06 ▼ $5.73	$99.42M	1.41	107,385 shs	66,361 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	0.00%	-4.56%	-4.67%	-31.23%	-97.60%
CGTX Cognition Therapeutics	0.00%	+5.82%	+8.71%	-28.28%	-29.25%
CPIX Cumberland Pharmaceuticals	0.00%	+14.55%	-2.40%	+27.97%	+126.63%
PYPD PolyPid	0.00%	+1.17%	+2.56%	+9.92%	+54.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$0.25 -3.1%	$0.28	$0.23 ▼ $11.79	$24.40M	1.8	109,131 shs	38,832 shs
CGTX Cognition Therapeutics	$1.04 -1.9%	$1.00	$0.55 ▼ $2.05	$98.90M	1.79	348,518 shs	336,211 shs
CPIX Cumberland Pharmaceuticals	$7.32 +1.8%	$7.29	$1.85 ▼ $9.28	$109.68M	0.13	54,920 shs	27,559 shs
PYPD PolyPid	$5.21 +3.6%	$4.87	$3.06 ▼ $5.73	$99.42M	1.41	107,385 shs	66,361 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	0.00%	-4.56%	-4.67%	-31.23%	-97.60%
CGTX Cognition Therapeutics	0.00%	+5.82%	+8.71%	-28.28%	-29.25%
CPIX Cumberland Pharmaceuticals	0.00%	+14.55%	-2.40%	+27.97%	+126.63%
PYPD PolyPid	0.00%	+1.17%	+2.56%	+9.92%	+54.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM BGM Group	1.00	Sell	N/A	N/A
CGTX Cognition Therapeutics	2.50	Moderate Buy	$3.33	220.51% Upside
CPIX Cumberland Pharmaceuticals	1.00	Sell	N/A	N/A
PYPD PolyPid	2.50	Moderate Buy	$11.33	117.53% Upside

Current Analyst Ratings Breakdown

Latest BGM, CGTX, CPIX, and PYPD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	BGM BGM Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
7/22/2026	PYPD PolyPid	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$12.00
7/21/2026	PYPD PolyPid	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
6/24/2026	CGTX Cognition Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	CPIX Cumberland Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	PYPD PolyPid	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/22/2026	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$3.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM BGM Group	$37.92M	0.64	N/A	N/A	$4.03 per share	0.06
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.39 per share	N/A
CPIX Cumberland Pharmaceuticals	$44.52M	2.46	$0.37 per share	19.96	$1.64 per share	4.46
PYPD PolyPid	N/A	N/A	N/A	N/A	$0.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM BGM Group	-$19.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	-$23.49M	-$0.17	N/A	N/A	N/A	N/A	-50.17%	-40.22%	11/5/2026 (Estimated)
CPIX Cumberland Pharmaceuticals	-$2.84M	-$0.71	N/A	N/A	N/A	-34.40%	-28.81%	-9.25%	11/3/2026 (Estimated)
PYPD PolyPid	-$34.17M	-$1.48	N/A	N/A	N/A	N/A	-311.08%	-150.83%	11/11/2026 (Estimated)

Latest BGM, CGTX, CPIX, and PYPD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/28/2026	Q2 2026	BGM BGM Group	N/A	-$0.01	N/A	-$0.0050	N/A	$12.15 million
8/12/2026	Q2 2026	PYPD PolyPid	-$0.3775	-$0.35	+$0.0275	-$0.35	$0.30 million	N/A
8/6/2026	Q2 2026	CGTX Cognition Therapeutics	-$0.0633	-$0.04	+$0.0233	-$0.04	$5.00 million	N/A
8/4/2026	Q2 2026	CPIX Cumberland Pharmaceuticals	-$0.13	-$0.20	-$0.07	-$0.29	$8.50 million	$0.17 million
7/21/2026	Q4 2025	BGM BGM Group	N/A	-$2.69	N/A	-$2.6850	N/A	$11.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PYPD PolyPid	N/A	N/A	N/A	N/A	N/A

Latest BGM, CGTX, CPIX, and PYPD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/13/2026	CPIX Cumberland Pharmaceuticals		$1.50			7/23/2026	7/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM BGM Group	N/A	1.25	0.73
CGTX Cognition Therapeutics	N/A	7.03	7.03
CPIX Cumberland Pharmaceuticals	N/A	0.96	0.96
PYPD PolyPid	N/A	1.35	1.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM BGM Group	N/A
CGTX Cognition Therapeutics	43.35%
CPIX Cumberland Pharmaceuticals	15.51%
PYPD PolyPid	26.47%

Insider Ownership

Company	Insider Ownership
BGM BGM Group	58.66%
CGTX Cognition Therapeutics	11.11%
CPIX Cumberland Pharmaceuticals	42.07%
PYPD PolyPid	24.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM BGM Group	471	97.22 million	40.19 million	N/A
CGTX Cognition Therapeutics	14	95.09 million	84.53 million	Not Optionable
CPIX Cumberland Pharmaceuticals	93	14.98 million	8.68 million	Optionable
PYPD PolyPid	75	19.08 million	14.37 million	No Data

BGM, CGTX, CPIX, and PYPD Headlines

Recent News About These Companies

PolyPid Announces Participation in Upcoming Fall Investor Conferences

September 15, 2026 | globenewswire.com

PolyPid Ltd. Ordinary Shares

September 14, 2026 | fxempire.comF

PolyPid Ltd. (NASDAQ:PYPD) Sees Large Drop in Short Interest

August 30, 2026 | marketbeat.com

PolyPid (PYPD) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ...

August 12, 2026 | finance.yahoo.com

PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript

August 12, 2026 | seekingalpha.com

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 12, 2026 | globenewswire.com

PolyPid's Double Win: D-PLEX₁₀₀ Gains NDA Acceptance and Priority Review, Ahead of Schedule (NASDAQ: PYPD)

July 31, 2026 | markets.businessinsider.com

PolyPid to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026

July 30, 2026 | quiverquant.comQ

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

July 30, 2026 | globenewswire.com

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

July 29, 2026 | globenewswire.com

PolyPid Ltd.: PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX100 in the U.S. and Canada

July 21, 2026 | finanznachrichten.de

PolyPid Locks in a Transformative Deal Worth Over $320 Million, With Additional Major Royalty Potential

July 21, 2026 | markets.businessinsider.com

PolyPid, Azurity sign surgical site infection drug deal

July 21, 2026 | reuters.com

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

July 21, 2026 | globenewswire.com

Lilly’s $780M Bet is Reshaping Surgical Infection Prevention, and PolyPid’s Asset is Hiding in Plain Sight

June 27, 2026 | theglobeandmail.com

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

June 1, 2026 | globenewswire.com

PolyPid Stock Short Interest Report | NASDAQ:PYPD | Benzinga

May 22, 2026 | benzinga.com

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

May 20, 2026 | globenewswire.com

PolyPid’s Earnings Call Signals Tightrope to Approval

May 20, 2026 | tipranks.com

PolyPid Ltd. (NASDAQ:PYPD) Q1 2026 Earnings Call Transcript

May 14, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM, CGTX, CPIX, and PYPD Company Descriptions

BGM Group NASDAQ:BGM

$0.25 -0.01 (-3.09%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.27 +0.02 (+8.76%)

As of 09/18/2026 07:09 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Cognition Therapeutics NASDAQ:CGTX

$1.04 -0.02 (-1.89%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.04 0.00 (-0.10%)

As of 09/18/2026 07:58 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Cumberland Pharmaceuticals NASDAQ:CPIX

$7.32 +0.13 (+1.81%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.52 +0.20 (+2.72%)

As of 09/18/2026 07:59 PM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

PolyPid NASDAQ:PYPD

$5.21 +0.18 (+3.58%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.18 -0.04 (-0.67%)

As of 09/18/2026 04:10 PM Eastern

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BGM, CGTX, CPIX, and PYPD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BGM, CGTX, CPIX, and PYPD Earnings

Compare Dividends

Latest BGM, CGTX, CPIX, and PYPD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BGM, CGTX, CPIX, and PYPD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM, CGTX, CPIX, and PYPD Company Descriptions

BGM Group NASDAQ:BGM

Cognition Therapeutics NASDAQ:CGTX

Cumberland Pharmaceuticals NASDAQ:CPIX

PolyPid NASDAQ:PYPD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BGM, CGTX, CPIX, and PYPD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BGM, CGTX, CPIX, and PYPD Earnings

Compare Dividends

Latest BGM, CGTX, CPIX, and PYPD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BGM, CGTX, CPIX, and PYPD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM, CGTX, CPIX, and PYPD Company Descriptions

BGM Group NASDAQ:BGM

Cognition Therapeutics NASDAQ:CGTX

Cumberland Pharmaceuticals NASDAQ:CPIX

PolyPid NASDAQ:PYPD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools